New combo therapy aims to knock out stubborn hepatitis b virus
NCT ID NCT07090759
First seen Jan 23, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests whether adding a new drug called GST-HG141 (Neracorvir) to standard antiviral treatment can better control chronic hepatitis B in people whose current medication isn't working well enough. About 526 adults aged 18-70 who have been on antivirals for over a year will receive either the new drug or a placebo. The main goal is to see if the virus level drops below a detectable limit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shulan(Hangzhou) Hospital
RECRUITINGHangzhou, Zhejiang, 310011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.